Optimi Health Corp.

Optimi Health Corp.

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence

VANCOUVER, British Columbia, Jan. 19, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to announce it has been granted an amendment to its H... Read More...

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats

Optimi Health Corp.VANCOUVER, British Columbia, Jan. 03, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant milestone in the granting of i... Read More...

Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement

VANCOUVER, British Columbia, Dec. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply agreement with Sunshine Earth Labs Ltd. (“Suns... Read More...

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

VANCOUVER, British Columbia, Nov. 28, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, streng... Read More...

Optimi Health Resolves Dispute

VANCOUVER, British Columbia, Nov. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pl... Read More...

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health Corp.VANCOUVER, British Columbia, Nov. 02, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is plea... Read More...

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

VANCOUVER, British Columbia, Sept. 14, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Compan... Read More...

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program

Optimi Health Corp.VANCOUVER, British Columbia, Sept. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers Optimi to embark on the f... Read More...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

VANCOUVER, British Columbia, Sept. 05, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it... Read More...

Optimi Health Announces Receipt of Purported Termination Notice

VANCOUVER, British Columbia, July 27, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further... Read More...

Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS

VANCOUVER, British Columbia, June 15, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Me... Read More...

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development

Optimi Health Corp.The Company’s entire cultivation facility has been mobilized to service supply agreementsVANCOUVER, British Columbia, May 04, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a CAD$1.2 million definitive supply agreement with a privat... Read More...

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement

Optimi Health Corp.The announcement follows a national reclassification of MDMA and psilocybin for therapeutic uses in Australia as a result of the years-long effort of Mind Medicine Australia and its dedicated supportersHighlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-t... Read More...

Optimi Health Announces Re-Appointments to Board of Directors

VANCOUVER, British Columbia, Jan. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company’s Annual General ... Read More...

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp.Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia, Sept. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and... Read More...

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Corp.EU-GMP, operational, and service excellence to drive world-class sales pipelineFunctional MushroomsFunctional mushrooms grown at Optimi Health facility in Princeton, British Columbia.Lion's ManeLion's Mane mushrooms grown at Optimi Health facility in Princeton, British Columbia.Optimi LifeOptimi Life BundleVANCOUVER, Br... Read More...

Optimi Health Provides Progress Report On Year Of Commercialization

Optimi Health Corp.Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertiseVANCOUVER, British Columbia, Sept. 01, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, ... Read More...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Corp.Deals position Optimi Life nutraceutical brand for international distributionOptimi LifeOptimi Life BundleOptimi LifeOptimi LifeOptimi LifeOptimi LifeVANCOUVER, British Columbia, Aug. 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by H... Read More...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Optimi Health Corp.CEO says licensing amendment positions Optimi to be a “global leader in the safe supply of EU-GMP Psilocybin, MDMA, and other psychedelics”Optimi HealthOptimi Health Analytical Laboratory in Princeton, BC.Optimi HealthInside of Optimi Health analytical laboratory.Optimi HealthOptimi Health analytical equipment.VANCOUVER... Read More...

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Corp.Blue Serenity (English)Optimi Health's, Blue Serenity psilocybin.Blue Serenity (English)Optimi Health's, Blue Serenity psilocybin.Blue Serenity Psilocybin PackagingOptimi Health's Blue Serenity psilocybin.Blue Serenity brings science and compassion together, will cement Thomas Hartle’s legacy as a Canadian psychedelic i... Read More...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

VANCOUVER, British Columbia, Aug. 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experie... Read More...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

VANCOUVER, British Columbia, July 13, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that... Read More...

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

Optimi Health Corp.Optimi Health Cultivation and Analytical FacilitiesOptimi Health Cultivation and Analytical FacilitiesOptimi Health Fruiting RoomOptimi Health fruiting room being prepared for second grow.VANCOUVER, British Columbia, June 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), ... Read More...

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Corp.Strategic partnership will focus on improving regulatory outcomes in therapist training and safe supply of psilocybinVANCOUVER, British Columbia, June 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessib... Read More...

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

VANCOUVER, British Columbia, May 31, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with ... Read More...

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

VANCOUVER, British Columbia, May 27, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with ... Read More...

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

VANCOUVER, British Columbia, May 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company’s road to ... Read More...

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Optimi Health Corp.Lab’s completion brings Company closer to full commercializationVANCOUVER, British Columbia, May 11, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, Briti... Read More...

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

VANCOUVER, British Columbia, May 09, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the... Read More...

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

VANCOUVER, British Columbia, April 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders... Read More...

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

Optimi Health Corp.VANCOUVER, British Columbia, March 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.“These mushrooms are an important milest... Read More...

Optimi Health Announces Investor Relations Agreement

VANCOUVER, British Columbia, March 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce it has entered into agreements with Kydde... Read More...